Kornimate/medical-research-clean huggingface dataset:
effects of nicorandil on angina symptoms in patients with coronary slow flow

Conditions: Slow Coronary Flow; Normal, or Near Normal Coronary Angiography; Stable Angina

Summary: slow coronary flow is an angiographically diagnosed phenomenon defined as delayed opacification of epicardial arteries in the absence of significant arterial narrowing and blockade. endothelial dysfunction at the level of microarteries have been proposed as the main pathological mechanism in this regard. available evidence suggest that standard anti-angina medications (e.g. nitroglycerin) that solely target large coronary trunks might not provide adequate symptomatic relief in patients with slow coronary flow phenomenon. it is hypothesized that anti-angina medications which exert vasodilatory effects in large coronary arteries as well as small dividing branches might be superior to nitroglycerin in amelioration of angina symptoms. the present randomized clinical trial was thus designed and conducted to compare the short-term efficacy of nicorandil (a dual-acting anti-angina medication with effects on both large and small coronary vessels) with nitroglycerin in a group of patients with slow coronary flow presented with frequent angina episodes.


Eligibility criteria:
inclusion criteria: * on coronary angiographic studies, arterial narrowing did not exceed 50% in any of the three main coronary arteries; ( * a delayed opacification in at least one of the main coronary arteries was documented. delayed opacification was defines as corrected timi frame count \> 23 fps exclusion criteria: * comorbid cardiovascular condition other than mild coronary atherosclerosis and coronary slow flow * refusal to participate * discontinuation of treatment * not returning for the follow up visit

Keywords: slow coronary flow phenomenon angina pectoris chest pain nicroandil
collection of samples from hiv-1 infected individuals for evaluation of the aptima hiv-1 assay

Conditions: HIV-1 Infection

Summary: the objective is to obtain plasma samples from human immunodeficiency virus type 1 (hiv-1) infected individuals that have viral loads across the dynamic range of the aptima hiv-1 assay. the plasma samples will be tested in a method comparison study to support the approval of the aptima hiv-1 assay on gen-probe's panther testing system. the objective of the method comparison study is to evaluate the clinical utility of the aptima hiv-1 assay by comparing the results to the fda-licensed cobas assay (roche molecular systems, inc., branchburg, new jersey) in plasma samples that have viral loads across the dynamic range of the aptima hiv-1 assay.


Eligibility criteria:
inclusion criteria * the subject has documented hiv infection * the subject is at least 15 years of age at the time of enrollment * for art subjects, subject has documented hiv-1 rna levels above the lower limit of quantitation of an fda-approved assay in a sample collected in the past 90 days. * the subject (and/or legally authorized representative, if allowed) is willing and able to provide written informed consent before providing a specimen (a minor will need the documented consent of his/her parent or legal guardian, unless the site has an institutional review board \[irb\]-approved waiver for parental consent for minors). exclusion criteria * a potential subject will be ineligible for the study if the subject, clinician, or medical record reports any of the following: * subject's hiv disease stage and/or current art status is unknown. * it is unknown if current or previous art was changed or stopped due to therapy failure. * for non-art subjects, subject was previously on art in the past 30 days * subject already participated in this study and subject's previous sample(s) was provided and not withdrawn (ie, subject has an evaluable sample in the study) * subject has a history of illness that the principal investigator (pi) or designee considers could interfere with or affect the conduct, results, and/or completion of the study * subject has a history of illness that the pi or designee considers could create an unacceptable risk to the subject if enrolled in the study
evaluation of allium ampeloprasum spp.iranicum cream effect for the management of hemorrhoids symptoms

Conditions: Hemorrhoids

Summary: purpose of study is evaluation of allium ampeloprasum spp.iranicum cream efficacy in management of symptomatic hemorrhoids in a double blind randomized placebo-control trial

purpose of study: evaluation of allium ampeloprasum spp.iranicum cream efficacy for the management of hemorrhoids study design:double blind randomized placebo-control trial, uni-central study population: participants having symptomatic hemorrhoids attending shiraz university of medical sciences clinics inclusion criteria: patients with symptomatic hemorrhoids(grade 1-4) without need to emergency operation according to physical examination exclusion criteria: participants having anal fissure or inflammatory bowel disease or history of gastrointestinal cancer sample size: 75 patients (tree groups) interventions: topical allium ampeloprasum cream/ placebo cream/anti-hemorrhoid cream time period: 3 week outcome measures: pain,itching, bleeding, defecate discomfort, total improvement, constipation

Eligibility criteria:
inclusion criteria * participants having symptomatic hemorrhoids(grade 1-4) without need to emergency operation according to physical examination * participants who do not use drugs other than the study drug and the control drug to treat their hemorrhoids during the study period: exclusion criteria: * participants having anal fissure or inflammatory bowel disease or history of gastrointestinal cancer * participants having hypersensitive predisposition or hypersensitive to allium ampeloprasum or history of skin hypersensivity * female participants under pregnancy or during breastfeeding period * participants complicated by serious cardio cerebro vascular diseases, hepatic and renal diseases, diseases of hemopoietic system or neurologic disorders or ascitis g- history of steroid or anticoagulant drug consumption

Keywords: hemorrhoids allium ampeloprasum herbal medicine traditional persian medicine
use of water warming/cooling garment to maintain a constant intraoperative core target temperature in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (hipec): a proof-of-concept study

Conditions: Hyperthermic Intraperitoneal

Summary: to look at the feasibility of using a water warming/cooling garment (called the allon system) to maintain a target body temperature during surgery and chemotherapy perfusion (a method of pouring chemotherapy throughout your abdominal cavity) without overheating or overcooling your body.

objectives: primary objectives: to evaluate the feasibility of using a water warming/cooling garment (allon system) to achieve and maintain a bladder temperature of ≥38°c for at least 30 minutes or longer during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy while avoiding core (esophageal) hyperthermia (≥39.5°c). secondary objective: to evaluate the safety for all study participants when using of the allon system strategy in achieving and maintaining a bladder temperature of ≥38°c for at least 30 minutes or longer during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy while avoiding core hyperthermia (≥39°c)

Eligibility criteria:
inclusion criteria: * adults patients (\>18 years old) * cytoreductive surgery with hyperthermic intraperitoneal chemotherapy with an expected duration of perfusion longer than 60 minutes * signed informed consent exclusion criteria: * america society of anesthesiology (asa)physical status \>4 * patient undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for recurrent disease. * patients with open wounds * patients with a history of thermoregulatory diseases such as spinal cord injury, thyroid disease, and malignant hyperthermia.
a multicenter placebo-controlled dose titration study to evaluate the efficacy and safety of sandostatin (sms 201-995) in the treatment of patients with acquired immunodeficiency related diarrhea

Conditions: Diarrhea; HIV Infections

Summary: to determine the efficacy and safety of sandostatin (octreotide) compared to placebo in controlling diarrhea which is a manifestation or complication of documented hiv infection and which is refractory (does not respond) to all known treatment classes.


Eligibility criteria:
inclusion criteria patients must have the following: * uncontrolled diarrhea that is either a manifestation or complication of documented hiv infection. * ability to communicate, participate, and comply with the requirements of the study. * capability of self administering injections of study medication or have responsible family member or companion who can. * given written consent prior to study entry. prior medication: required: * at least two weeks of conventional dosing regimens of antidiarrheal medication (e.g.: * lomotil, imodium, paregoric) within one month prior to study entry. or patients with evidence of upper or lower gi infection(s) for which there is approved, potentially curative therapy must have failed appropriate treatment for at least two weeks. exclusion criteria co-existing condition: patients with the following conditions or symptoms are excluded: * evidence of underlying immunosuppressive disease other than due to hiv. * diarrhea caused by a known gastrointestinal disorder such as idiopathic ulcerative colitis, crohn's disease, acute stool culture positive bacterial colitis (documented within the last 2 weeks prior to study entry and not having at least 2 weeks of antibiotic therapy), pseudomembranous colitis (clostridium difficile toxin positive), short gut syndrome, chronic pancreatitis (alcoholic or idiopathic), ischemic bowel disease, or enteroenteric fistulae. patients with the following are excluded: * diarrhea that can be controlled with conventional antidiarrheal agents. * stool weight at either of the 2 baseline periods that average \< 500 g/day. * evidence of underlying immunosuppressive disease other than due to hiv. * diarrhea caused by other gastrointestinal disorders not related to hiv. prior medication: excluded: * previously treated with sandostatin as an anti-diarrheal agent. * experimental antidiarrheal drugs within one month of study entry. present intravenous drug abuse.

Keywords: octreotide diarrhea acquired immunodeficiency syndrome aids-related complex
family-based and adolescent residential drug treatment

Conditions: Substance Use; Delinquency

Summary: the fundamental objective of this study is to compare the effectiveness of an intensive in-home family-based treatment, multidimensional family therapy, with a multifaceted residential treatment, adolescent residential treatment, over 4 years post-intake and to delineate the mechanisms of change for each treatment. the study targets dually- diagnosed adolescent drug abusers recommended for residential treatment.

aim 1: to compare the effectiveness of residential treatment with outpatient, family-based treatment multiple outcomes including substance use, mental health, school functioning, family function and delinquency among dually diagnosed adolescents. hypothesis 1. from intake to 2 months, residential treatment will show better outcomes than the family based treatment. between 2 months and 18 months, family based treatment will show better outcomes than residential. between 18 months and four years post intake, outpatient family based treatment will maintain its treatment gains, while the residential treatment condition will show an increase in these same symptoms and behaviors. aim 2: to examine the relationship between predictors (family, peer, educational/vocational functioning and involvement in post-treatment services), and outcomes (drug use, co-morbid symptoms, and criminal behavior) during the four-year post intake period. hypothesis 2a. family functioning, educational/vocational functioning, and peer relationships measured at discharge will predict drug use, co-morbid symptoms, and criminal behaviors though the four year longer term follow up period. hypothesis 2b. family functioning, educational/vocational functioning, peer relationships, and involvement in post-treatment services during the post treatment period will predict drug use, co-morbid symptoms, and criminal behavior through the longer term follow up period. research question 1. is the rate of change in family functioning, educational/vocational functioning, peer relationships, and involvement in post-treatment services related to the rate of change in drug use, co-morbid symptoms, and criminal behavior?

Eligibility criteria:
inclusion criteria: * youth between the ages of 13 and 17 * referred to atp for residential substance abuse treatment in youth dual diagnosis program * dually diagnosed for substance abuse or dependence and at least one of the following co-morbid conditions: major depressive disorder, bipolar disorder, i conduct disorder, oppositional defiant disorder, * at least one parent or parent-figure can be located at the time of referral. * obtain informed consent from a parent or formal guardian and assent from youth to participate in the study. exclusion criteria: * have any of the following disorders: mental retardation, eating disorders, schizophrenia, or pervasive developmental disorders. * current suicidality.

Keywords: adolescents residential treatment outpatient treatment substance abuse delinquency family therapy multidimensional family therapy
predictive value of doppler rsi for prediction of aki in septic patients in icu

Conditions: Acute Kidney Injury; Sepsis

Summary: acute kidney injury (aki) diagnosis is based on rising creatinine. intrarenal vasoconstriction occurs earlier and measuring flow resistance in the renal circulation (renal resistive index (rri)) could become part of vital organ function assessment using doppler ultrasound. the aim of this study is to predict aki in septic patients in icu by measuring rri on admission by comparing two groups of patients, first group with rri of normal value (0.6-0.7) and the other group with high rri more than 0.7 and both with normal renal function on admission.

patients who have criteria of sepsis, with normal renal function on admission will undergo renal doppler ultrasound examination to measure renal resistive index. patients will be divided into 2 groups: 1. group (a) patients with renal resistive index between 0.6 and 0.7 (normal rri). 2. group (b) patients with renal resistive index more than 0.7 (high rri).

Eligibility criteria:
inclusion criteria: 1. patients who have criteria of sepsis on admission which include two or more of sirs which include: (temperature \>38°c or \ 90/min, respiratory rate \>20/min or paco2 \ 12000/mm3 or \ 10% immature bands.) in addition to suspected or confirmed infection. 2. patients who have normal renal function on admission. exclusion criteria: 1. currently recovering from an aki at the time of inclusion and renal impairment on admission. 2. patients with obstructive renal failure, renal artery stenosis were excluded from this study. 3. patients on chemotherapy and/or radiotherapy. 4. pregnancy.

Keywords: acute kidney injury sepsis
study of protein metabolism in healthy older subjects

Conditions: Malnutrition

Summary: this is a randomized, double-blinded, crossover study to evaluate muscle protein metabolism during fasting and feeding in healthy older subjects.


Eligibility criteria:
inclusion criteria: * age ≥ 60 and ≤ 75 years * body mass index (bmi) \> 23.0 to \< 30.0 * ability (with or without the aid of an assistive device) to climb a flight of 10 stairs or walk an equivalent of 1 city block without assistance * currently not participating in a formal exercise or training program and agrees to refrain from intense physical activity from screening through the completion of the study. exclusion criteria: * diagnosis of diabetes * active pursuit of weight loss * poorly controlled hypertension or hypotension * untreated hypothyroidism or hyperthyroidism * anemia or abnormally functioning kidneys or liver * a significant cardiovascular event within ≤ 6 months; or stated history of congestive heart failure; or evidence of clinically active cardiovascular disease assessed during the screening ekg * peripheral arterial disease or other diseases that preclude proper limb blood flow * chronic, contagious, infectious disease * current infection or corticosteroid treatment within the last 3 months * clotting or bleeding disorders, stated history of deep vein thrombosis (dvt) and/or a known hypercoagulable condition * in condition deemed unsuitable for study based upon study physician assessment * surgery requiring \>2 days of hospitalization in the last 3 weeks and/or planned elective surgery requiring \>2 days of hospitalization during the course of the study * current active malignant disease or was treated within the last 6 months for cancer * an amputee * obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease * diagnosed with, or has a history of severe dementia or delirium, eating disorder, history of significant neurological or psychiatric disorder, alcoholism, substance abuse * cannot refrain from taking * high doses of fish oil, or omega-3 supplements, or high doses of vitamin d * medications/dietary supplements/herbals or substances that are considered anabolic, or reduce weight * any pulmonary anti-inflammatory medication or bronchodilators on the day of and 48 hours prior to study visits 1 and 2 * nsaids or acetaminophen on the day of and 48 hours prior to study visits 1 and 2 * chronic use of nicotine * allergic or intolerant to any ingredient found in the study products
treatment of patients with chronic osteoarthritis with ginger kidney compress - a randomized, controlled trial

Conditions: Osteoarthritis

Summary: the investigators hypothesize that by a 5-week treatment with ginger kidney compresses at least 2 of 3 main symptoms of the womac (pain, stiffness, functionality) will be reduced at least 30% at the time of the post-measurement (after 5 weeks of therapy) in comparison to the respective control group (waitlist).


Eligibility criteria:
inclusion criteria: * chronic osteoarthritis, mainly osteoarthritis of the knee * osteoarthritis symptoms for at least six months * written consent to participate in the study * age: 30 years and more exclusion criteria: * rheumatoid arthritis * fibromyalgia * oncological or other serious diseases * use of corticosteroids * nephropathy * non-intact skin conditions in the area of application * hypersensitivity / allergy to ginger * simultaneous participation in another clinical trial
esophageal temperature during pvi using q-dot micro

Conditions: Atrial Fibrillation Paroxysmal

Summary: this study will assess how two different ablation strategies, using two different ablation catheters during catheter ablation for paroxysmal atrial fibrillation, affect the temperature of the esophagus during ablation, and the risk of injury to the esophagus.

this is a prospective randomized controlled trial, studying patients undergoing ablation involving pulmonary vein isolation for paroxysmal atrial fibrillation. patients will be assigned to undergo conventional high-power short-duration ablation or temperature-controlled very-high-power short-duration ablation, and esophageal outcomes including temperature changes during ablation and esophageal injury as assessed by post-procedure capsule endoscopy will be compared between the groups. the hypothesis is that very-high-power short-duration ablation will lead to lower rises in esophageal temperature and lower rates of esophageal findings during capsule endoscopy.

Eligibility criteria:
inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged greater than or equal to 18 years 4. diagnosed with paroxysmal atrial fibrillation 5. undergoing rf catheter ablation for treatment of paroxysmal atrial fibrillation that will involve circumferential point-by-point radiofrequency ablation pulmonary vein isolation with no additional left atrial posterior wall ablation planned exclusion criteria: 1. patients who have undergone prior left atrial ablation procedures. 2. patients where the use of the q-dot micro ablation catheter in qmode+ (i.e. temperature-controlled very-high-power short-duration ablation) is felt to be unsafe. 3. patients who have contraindications to capsule endoscopy, or gi conditions that may increase the risks of capsule endoscopy (e.g. esophageal strictures, inflammatory bowel disease, etc) 4. any records flagged "break the glass" or "research opt out."

Keywords: atrial fibrillation esophageal thermal injury
electrical stimulation to recover greater range of motion after surgery

Conditions: Thumb Joint Stiffness

Summary: background one of the potentially debilitative complications of operative repair and subsequent immobilization is stiffness that appears secondary to inflammation and adhesions. to prevent such a physical impairment, active joint mobilization has shown to be efficient. however, adhesions sometimes remain despite the therapy. due to the viscoelastic nature of the biological tissues, if a technique can enable to extend the muscle ability to impose a maximal steady stress on adhesions, adhesion deformation should be greater and range of motion deficit should be reduced. within that context, the purpose of the present study was to assess the real-time effects of superimposed electrical stimulation (ses) on maximal voluntary muscular contraction (vol) over time and to assess ses effects on range of motion recovery in thumb stiff joint. methods and findings the aim of the first experiment was to examine the real-time effects of tetanic ses on the maximal volitional level of force over repeated contractions of the triceps brachii muscle. to address this goal, seventeen subjects participated voluntarily in this study. two features of the muscular force were assessed: the peak force (1) and the impulse (2). these two dependent variables were measured during 500 sec - including 50 maximal force productions of 4 sec each- in two randomized conditions of vol and ses. when considering the 50 trials as a whole, exerted force was higher in the ses than in the vol condition for both peak force and impulse (p\<.05). over time, peak force and impulse decreased consistently in vol starting between the 20th and 30th trials whereas they were maintained in ses condition (p\<.05). the aim of the second experiment was to compare the effects of vol and ses on the range of flexion recovery of the stiff metacarpophalangeal joint following operative repair of the ulnar collateral ligament of the thumb. to address this goal, eight patients participated voluntarily. range of motion, oedema and pain were assessed before and after the two randomised conditions of vol and ses.


Eligibility criteria:
inclusion criteria: * loss of range of flexion in the involved metacarpophalangeal joint of at least ten degrees when compared to the opposite thumb * more than eight weeks post-surgery exclusion criteria: * do not meet the inclusion criteria

Keywords: thumb ulnar collateral ligament superimposed electrical stimulation stiffness adhesions